Company / Accounts Receivable
AVADEL PHARMACEUTICALS PLC Accounts Receivable History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$34.1M
FY2024
5-year range
$0 / $34.1M
FY2020-FY2024
Trend
+181.7%
vs FY2023
Sector context
#79 of 113
Health Care
What the data says
At $34M, AVADEL PHARMACEUTICALS PLC's accounts receivable ranks #79 of 113 in the Health Care sector. Improved from $0 to $34M over the past 2 years.
Based on SEC 10-K filings.
$34M in FY2024 with a 5-year CAGR of +32.7%.
Improved from $0 to $34M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- +32.7%
- 10-Year CAGR
- -
Sector benchmark
#79 of 113 in Health CareTop 70% of 113This company $34.1M Sector average $1.1B
▼
-97.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +32.7%, indicating consistent growth.
- In FY2024, accounts receivable increased 181.7% year-over-year.
- Ranks #79 out of 113 companies in the Health Care sector.
- Lowest accounts receivable in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score 0.94 (distress zone, below 1.8 threshold)
- Negative profit margin: -28.9%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $34.1M | +181.7% |
| FY2023 | $12.1M | - |
| FY2022 | $0 | - |
| FY2021 | - | - |
| FY2020 | $0 | -100.0% |
| FY2019 | $8.3M | -26.9% |
| FY2018 | $11.3M | -23.4% |
| FY2017 | $14.8M | -17.1% |
| FY2016 | $17.8M | +138.3% |
| FY2015 | $7.5M | +345.9% |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026